John Kinuthia

John Kinuthia

Auto-generated profile, based on publicly available information

John Kinuthia

Department of Global Health, University of Washington , Seattle, Washington

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in The Lancet HIV
Verified
Journal Article
Closed access
JKJohn Kinuthia
John Kinuthia
JPJillian Pintye
Jillian Pintye
FAFelix Abuna
Felix Abuna
KMKenneth K Mugwanya
Kenneth K Mugwanya
HLHarison Lagat
Harison Lagat
YFYvonne F Fondo
Yvonne F Fondo

8 January 2020 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
DJDvora Leah Joseph-Davey
Dvora Leah Joseph-Davey
JPJillian Pintye
Jillian Pintye
JBJared M Baeten
Jared M Baeten
GAGrace Aldrovandi
Grace Aldrovandi
RBRachel Baggaley
Rachel Baggaley
FGfor the PrEP in Pregnancy Working Group
for the PrEP in Pregnancy Working Group
Introduction: HIV incidence is high during pregnancy and breastfeeding with HIV acquisition risk more than doubling during pregnancy and the postpartum period compared to when women are not pregnant. The World Health Organization recommends offering pre‐exposure prophylaxis (PrEP) to pregnant and postpartum women at substantial risk of HIV infection. However, maternal PrEP national guidelines differ and most countries with high maternal HIV incidence are not offering PrEP. We conducted a systematic review of recent research on PrEP safety in pregnancy to inform national policy and rollout.Methods: We used a standard Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) approach to conduct a systematic review by searching for completed, ongoing, or planned PrEP in pregnancy projects or studies from clinicaltrials.gov, PubMed and NIH RePORTER from 2014 to March 2019. We performed a systematic review of studies that assess tenofovir disoproxil fumarate (TDF)‐based oral PrEP safety in pregnant and breastfeeding HIV‐uninfected women.Results and discussion: We identified 14 completed (n = 5) and ongoing/planned (n = 9) studies that evaluate maternal and/or infant outcomes following PrEP exposure during pregnancy or breastfeeding. None of the completed studies found differences in pregnancy or perinatal outcomes associated with PrEP exposure. Nine ongoing studies, to be completed by 2022, will provide data on >6200 additional PrEP‐exposed pregnancies and assess perinatal, infant growth and bone health outcomes, expanding by sixfold the data on PrEP safety in pregnancy. Research gaps include limited data on (1) accurately measured PrEP exposure within maternal and infant populations including drug levels needed for maternal protection; (2) uncommon perinatal outcomes (e.g. congenital anomalies); (3) infant outcomes such as bone growth beyond one year following PrEP exposure; (4) outcomes in HIV‐uninfected women who use PrEP during pregnancy and/or lactation.Conclusions: Expanding delivery of PrEP is an essential strategy to reduce HIV incidence in pregnancy and breastfeeding women. Early safety studies of PrEP among pregnant women without HIV infection are reassuring and ongoing/planned studies will contribute extensive new data to bolster the safety profile of PrEP use in pregnancy. However, addressing research gaps is essential to expanding PrEP delivery for women in the context of pregnancy.

2 January 2014 in AIDS
Verified
Journal Article
Closed access
AOAlfred Onyango Osoti
Alfred Onyango Osoti
GJGrace John-Stewart
Grace John-Stewart
JKJames Kiarie
James Kiarie
BRBarbra Richardson
Barbra Richardson
JKJohn Kinuthia
John Kinuthia
CFCarey Farquhar
Carey Farquhar
Background: HIV testing male partners of pregnant women may decrease HIV transmission to women and promote uptake of prevention of mother-to-child HIV transmission (PMTCT) interventions. However, it has been difficult to access male partners in antenatal care (ANC) clinics. We hypothesized that home visits to offer HIV testing to partners of women attending ANC would increase partner HIV testing. Methods: Women attending their first ANC were enrolled, interviewed using smartphone audio-computer-assisted self-interviews and randomized to home visits or written invitations for male partners to come to clinic, if they were married or cohabiting, unaccompanied by partners and had no prior couple HIV counselling and testing (CHCT). Enrolled men were offered CHCT (HIV testing and mutual disclosure). Prevalence of CHCT, male HIV seropositivity, couple serodiscordance and intimate partner violence, reported as physical threat from partner, were compared at 6 weeks. Results: Among 495 women screened, 312 were eligible, and 300 randomized to clinic-based or home-based CHCT. Median age was 22 years (interquartile range 20–26 years), and 87% were monogamous. CHCT was significantly higher in home-visit than in clinic-invitation arm (n = 128, 85% vs. n = 54, 36%; P < 0.001). Home-arm identified more HIV-seropositive men (12.0 vs. 8.0%; P = 0.248) and more HIV-discordant couples (14.7 vs. 4.7%; P = 0.003). There was no difference in intimate partner violence. Conclusion: Home visits of pregnant women were safe and resulted in more male partner testing and mutual disclosure of HIV status. This strategy could facilitate prevention of maternal HIV acquisition, improve PMTCT uptake and increase male HIV diagnosis.

24 September 2015 in AIDS
Verified
Journal Article
Closed access
JKJohn Kinuthia
John Kinuthia
ADAlison L. Drake
Alison L. Drake
DMDaniel Matemo
Daniel Matemo
BRBarbra A. Richardson
Barbra A. Richardson
CZClement Zeh
Clement Zeh
GJGrace John-Stewart
Grace John-Stewart
Objective: The objective of this study is to determine the risk and cofactors for HIV acquisition during pregnancy and postpartum. Design: A prospective cohort study Methods: Pregnant women in western Kenya were enrolled if HIV seronegative at that visit or within 3 months. Serial HIV nucleic acid amplification tests (NAATs) were conducted at 1 to 3-month intervals to 9 months postpartum. Genital swabs were collected for detection of chlamydia and gonorrhoea at baseline, and for trichomonas, bacterial vaginosis and yeast at baseline and follow-up. Results: Among 1304 pregnant women, median age was 22 years, 78% were married for a median of 4 years, 66% reported knowing partner HIV status and 8% reported using condoms. Study retention was 98%. During 1235 person-years of follow-up, HIV incidence was 2.31/100 person-years [95% confidence interval (95% CI) 0.71–4.10]. Incident HIV was associated with syphilis (hazard ratio 9.18, 95% CI 2.15–39.3), chlamydia (hazard ratio 4.49, 95% CI 1.34–15.0), bacterial vaginosis (hazard ratio 2.91, 95% CI 1.25–6.76), yeast (hazard ratio 3.46, 95% CI 1.46–8.19), sexually transmitted infection (STI) history (hazard ratio 3.48, 95% CI 1.31–9.27), lifetime number of sex partners (hazard ratio 1.19, 95% CI 1.03–1.37), partner age discordance (hazard ratio 1.07 per year, 95% CI 1.02–1.13) and shorter marriage (hazard ratio 1.19 per year, 95% CI 1.03–1.38). No women with incident HIV reported an HIV-infected partner. In multivariate analyses, chlamydia, older partners and yeast infection remained significant; however, power was limited. Conclusion: Pregnant and lactating women may not perceive HIV risk and rarely used condoms. Prevention and treatment of genital infections and risk stratification to identify women for pre-exposure prophylaxis (PrEP) could decrease HIV acquisition in pregnant/lactating women.

1 January 2017 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
KRKeshet Ronen
Keshet Ronen
CMChristine J. McGrath
Christine J. McGrath
ALAgnes C. MBChB Langat
Agnes C. MBChB Langat
JKJohn MBChB Kinuthia
John MBChB Kinuthia
DODanvers Msc Omolo
Danvers Msc Omolo
GJGrace John-Stewart
Grace John-Stewart
Background: Rates of pregnancy and HIV infection are high among adolescents. However, their engagement in prevention of mother-to-child HIV transmission (PMTCT) services is poorly characterized. We compared engagement in the PMTCT cascade between adult and adolescent mothers in Kenya. Methods: We conducted a nationally representative cross-sectional survey of mother–infant pairs attending 120 maternal child health clinics selected by probability proportionate to size sampling, with a secondary survey oversampling HIV-positive mothers in 30 clinics. Antenatal care (ANC) attendance, HIV testing, and antiretroviral (ARV) use were compared between adolescent (age ≤19 years) and adult mothers using χ2 tests and logistic regression. Results: Among 2521 mothers, 278 (12.8%) were adolescents. Adolescents were less likely than adults to be employed (16.5% vs. 37.9%), married (66.1% vs. 88.3%), have intended pregnancy (40.5% vs. 58.6%), or have disclosed their HIV status (77.5% vs. 90.7%) (P < 0.01 for all). Adolescents were less likely than adults to attend ≥4 ANC visits (35.2% vs. 45.6%, P = 0.002). This effect remained significant when adjusting for employment, household crowding, pregnancy intention, gravidity, and HIV status [adjusted odds ratio (95% confidence interval) = 0.54 (0.37 to 0.97), P = 0.001]. Among 2359 women without previous HIV testing, 96.1% received testing during pregnancy; testing levels did not differ between adolescents and adults. Among 288 HIV-positive women not on antiretroviral therapy before pregnancy, adolescents were less likely than adults to be on ARVs (65.0% vs. 85.8%, P = 0.01) or to have infants on ARVs (85.7% vs. 97.7%, P = 0.005). Conclusions: Adolescent mothers had poorer ANC attendance and uptake of ARVs for PMTCT. Targeted interventions are needed to improve retention of this vulnerable population in the PMTCT cascade.

1 October 2010 in Current HIV Research
Verified
Journal Article
Closed access
PDF file
JKJohn Kinuthia
John Kinuthia
JKJames N. Kiarie
James N. Kiarie
CFCarey Farquhar
Carey Farquhar
BRBarbra Richardson
Barbra Richardson
RNRuth Nduati
Ruth Nduati
GJGrace John-Stewart
Grace John-Stewart
Objectives: To estimate HIV-1 incidence and cofactors for HIV-1 incidence during pregnancy and postpartum. Design: Retrospective study among women who were HIV seronegative during pregnancy. Methods: Mothers accompanying their infants for routine 6-week immunizations at 6 maternal child health clinics in Nairobi and Western Kenya were tested for HIV-1 after completing a questionnaire that included assessment of sociodemographics, obstetric history and HIV-1 risk perception. Results: Of 2,135 mothers who had tested HIV-1 seronegative antenatally, 2,035 (95.3%) accepted HIV-1 re-testing at 6 weeks postpartum. Of these, 53 (2.6%) were HIV-1 seropositive yielding an estimated HIV-1 incidence of 6.8 (95% CI: 5.1-8.8) per 100 woman-years). Mothers who seroconverted were more likely to be employed (45.3% vs 29.0%, p=0.01), married (96.2 vs 86.6%, p=0.04) and from a higher HIV-1 prevalence region (60.4% in Western Kenya vs 28.8% in Nairobi, p < 0.001). Among married women, those in polygamous relationship were significantly more likely to seroconvert (19.6% vs 6.7%, p < 0.001). In multivariate analysis, region and employment independently predicted seroconversion. Conclusions: Repeat HIV-1 testing in early postpartum was highly acceptable and resulted in detection of substantial HIV-1 incidence during pregnancy and postpartum period. Within prevention of mother-to-child HIV-1 transmission programs strategic approaches to prevent maternal HIV-1 acquisition during pregnancy are urgently needed.